ArticleJournal, genetic engineering & biotechnology2026
Evaluation of lncRNA PVT1 rs13255292 variant and serum E-cadherin levels in breast cancer.
Article in Journal, genetic engineering & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer (BC) is the most frequent malignancy, and a prime cause of lethality related to cancer worldwide. Genetic research, particularly on lncRNA, shows prospects for BC management. PVT1 can activate many tumorigenic pathways. This contributes to angiogenesis and pathological progression. This study examined the association between the PVT1 rs13255292 variants and serum E-cadherin levels with BC risk, hormone receptor status, and tumor grade. METHODOLOGY: Genotyping was performed on 120 blood samples (20 controls, 100 BCE patients, 100 stratified by histological grade: G1 = 3, G2 = 74, G3 = 23) using TaqMan assays. Also, Patients were classified as luminal A (n = 79) or non-luminal A (luminal B, HER2-enriched, TNBC) (n = 21). Serum E-cadherin was evaluated by an ELISA kit.
resultsFindings revealed a statistically significant association between the PVT1 rs13255292 non-risk CC genotype and luminal A subtype patients, suggesting a potential protective effect. E-cadherin levels were significantly declined in BC patients compared to controls. Based on the histological grades, a notable reduction was detected in advanced G3 compared to G2. While serum E-cadherin showed promise as a non-invasive diagnostic biomarker. Also, the genotype-specific analysis indicated a trend toward higher E-cadherin expression in CC carriers' group, though without statistical significance.
conclusionThe current finding underscores that the CC genotype is associated with less aggressive luminal A tumors. It also reveals an inverse link between tumor grade and E-cadherin serum levels. These findings suggest that combining genetic screening of PVT1 variants with E-cadherin surveillance could enhance prognostic stratification in BC management. Further validation in larger cohorts is required to confirm clinical utility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.